【药物大比拼】罗氟司特与扎鲁司特功效一样吗？

Roflumilast is an oral selective phosphodiesterase 4 (PDE4) inhibitor, a benzamide compound, and is currently the only phosphodiesterase IV (PDE-4) inhibitor approved for oral treatment of respiratory diseases. By selectively inhibiting PDE4, it blocks the transmission of inflammatory response signals, thereby inhibiting the damage to lung tissue caused by respiratory diseases such as COPD and asthma. It has been shown to inhibit COPD-related inflammation with a novel mode of action. Unique properties to help better manage patients with COPD: When used in combination with a bronchodilator to treat patients with the most severe forms of COPD, roflumilast provides the additional benefit of further reducing symptoms and rates of disease exacerbations, making it the first drug to target a specific phenotype of COPD in patients with severe airflow limitation associated with chronic cough and phlegm and a history of recurrent disease exacerbations.

Zafirlukast, as a leukotriene receptor antagonist of peptides LTC4, LTD4, LTE4 and other hypersensitive slow-reacting substances, competitively inhibits the activity of leukotrienes and effectively prevents airway edema caused by the increase in vascular permeability caused by leukotriene polypeptides. It also inhibits the infiltration of airway eosinophils produced by leukotriene polypeptides, reduces tracheal constriction and inflammation, and relieves asthma symptoms. This product is highly selective and only acts on leukotriene receptors without affecting prostaglandin, thromboxane, cholinergic and histamine receptors. This medicine is used to prevent asthma attacks and should be used continuously. For adults and children over 12 years old (including 12 years old), the starting dose should be 20 mg bid, and the general maintenance dose is 20 mg bid. The dose should be gradually increased to a maximum dose of 40 mg once a day. The effect may be better when used twice a day, and the dosage should not exceed the maximum recommended dose. Because food can reduce the bioavailability of zafirlukast, avoid taking this drug with food.

There are some differences between the two drugs. It is recommended that patients go to the hospital to consult with the relevant doctor about which one should be used.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.